Sex | Classifiers | AUROC^{*} | 95% CI | rdCV^{†} accuracy | Permutation^{‡} P value | 2 × 2^{§} accuracy | 2 × 2 sensitivity | 2 × 2 specificity |

Males | 8-analyte example^{¶} | 0.94 | 0.84–1.0 | 0.84 | 0.001 | 0.90 | 0.91 | 0.89 |

1-analyte example^{#} | 0.71 | 0.50–0.88 | 0.62 | 0.009 | 0.72 | 0.73 | 0.72 | |

Females | 13-analyte example^{||} | 0.96 | 0.87–1.0 | 0.90 | 0.001 | 0.93 | 0.91 | 0.95 |

1-analyte example^{#} | 0.68 | 0.42–0.86 | 0.58 | 0.009 | 0.68 | 0.70 | 0.67 |

*n*= 18 control males and 22 CFS males, and*n*= 21 control females and 23 CFS females.↵* AUROC, area under the receiver operator curve reflects the overall accuracy of diagnosis using these analytes.

↵

^{†}rdCV, repeated random subsample (2/3 in, 1/3 out) double cross-validation.↵

^{‡}Permutation*P*values represent the probability that the RF classification of cases and controls using the specified analytes could be obtained by chance.↵

^{§}Values calculated by standard 2 × 2 contingency table analysis.↵

^{¶}8:analytes in males, phosphatidyl choline PC(16:0/16:0), glucosylceramide GC(18:1/16:0), 1-P5C, FAD, pyroglutamic acid (also known as 5-oxoproline), HICA, l-serine, and lathosterol.↵

^{#}1-analyte: phosphatidyl choline PC(16:0/16:0).↵

^{||}13-analytes in females: THC(18:1/24:0), phosphatidyl choline PC(16:0/16:0), hydroxyproline, ceramide(d18:1/22:2), lathosterol, adenosine, phosphatidylinositol PI(16:0/16:0), FAD, 2-octenoylcarnitine, phosphatidyl choline plasmalogen PC(22:6/P18:0), phosphatidyl choline PC(18:1/22:6), 1-P5C, and CDCA.